Kivu Bioscience to Present Preclinical Data on Next-Gen ADC Programs

Got story updates? Submit your updates here. ›

Kivu Bioscience, a clinical-stage biotech company, will present preclinical data on two of its next-generation antibody-drug conjugate (ADC) programs at the upcoming American Association for Cancer Research (AACR) Annual Meeting in 2026. The data highlights the strong anti-tumor activity, favorable pharmacokinetics, and improved tolerability of the PTK7-targeting ADC KIVU-107, as well as the potent preclinical results and enhanced stability of the CEACAM5-targeting ADC KIVU-305 across colorectal and other solid tumor models.

Why it matters

Antibody-drug conjugates are an emerging class of targeted cancer therapies that combine the specificity of monoclonal antibodies with the cell-killing power of cytotoxic drugs. The positive preclinical data on Kivu's next-gen ADC candidates suggests they could represent promising new treatment options for solid tumors, an area of high unmet medical need.

The details

Kivu Bioscience's lead ADC program, KIVU-107, targets the PTK7 protein, which is overexpressed in many solid tumors. The company's data shows KIVU-107 demonstrated strong anti-tumor activity, favorable pharmacokinetics, and improved tolerability in preclinical studies. Meanwhile, the CEACAM5-targeting ADC KIVU-305 exhibited potent preclinical activity and enhanced stability across colorectal and other solid tumor models.

• The data will be presented at the AACR Annual Meeting in 2026.

What’s next

Kivu Bioscience plans to advance both KIVU-107 and KIVU-305 into clinical trials following the presentation of the preclinical data at AACR 2026.